Department of General Surgery and Liver Transplantation Center, Capital Medical University Affiliated Youan Hospital, Beijing 100069, China.
Capital Medical University Affiliated Youan Hospital, Beijing 100069, China.
Biomed Res Int. 2020 Mar 23;2020:5353695. doi: 10.1155/2020/5353695. eCollection 2020.
Circulating microRNA-122 (miR-122) has been recognized as a marker of hepatocellular carcinoma (HCC). The current meta-analysis was performed to quantitatively evaluate the diagnostic performance of circulating miR-122 for HCC.
Related studies that evaluated the diagnostic performance of circulating miR-122 determined from pathophysiological examination for HCC were obtained by systematic searches of the PubMed and Embase databases. A randomized fixed effects model was applied according to the heterogeneity among studies. The pooled sensitivity, specificity, and area under the summary receiver operating characteristic curve (AUC) were calculated to evaluate the diagnostic accuracy. Publication bias was detected by Deeks' funnel plot asymmetry test.
Thirteen studies providing data for 920 HCC patients and 1217 controls were included in the meta-analysis. The pooled sensitivities, specificities, and AUCs of serum miR-122 were 0.76, 0.75, and 0.82, respectively, for discriminating HCC patients from overall controls; 0.85, 0.83, and 0.91, respectively, for discriminating HCC patients from healthy controls; 0.79, 0.82, and 0.87, respectively, for discriminating HCC from HBV or HCV infection; and 0.65, 0.75, and 0.74, respectively, for discriminating HCC from liver cirrhosis or dysplastic nodule formation. No significant publication bias was detected.
Serum miR-122 confers moderate efficacy for discriminating HCC patients from healthy controls or patients with HBV or HCV infection, but not for discriminating HCC patients from those with liver cirrhosis or dysplastic nodule formation.
循环 microRNA-122 (miR-122) 已被认为是肝细胞癌 (HCC) 的标志物。本荟萃分析旨在定量评估循环 miR-122 对 HCC 的诊断性能。
通过系统搜索 PubMed 和 Embase 数据库，获取评估来自病理生理学检查的循环 miR-122 对 HCC 诊断性能的相关研究。根据研究之间的异质性，采用随机固定效应模型。计算汇总受试者工作特征曲线下的面积 (AUC) 以评估诊断准确性。通过 Deeks 漏斗图不对称检验检测发表偏倚。
荟萃分析共纳入 13 项研究，共 920 例 HCC 患者和 1217 例对照。血清 miR-122 区分 HCC 患者与总体对照、健康对照、HBV 或 HCV 感染、肝硬化或异型增生结节形成的患者的汇总敏感性、特异性和 AUC 分别为 0.76、0.75 和 0.82、0.85、0.83 和 0.91、0.79、0.82 和 0.87、0.65、0.75 和 0.74。未发现明显的发表偏倚。
血清 miR-122 对区分 HCC 患者与健康对照或 HBV 或 HCV 感染患者具有中等疗效，但对区分 HCC 患者与肝硬化或异型增生结节形成患者的效果不佳。
